A Study of Olverembatinib in SDH-deficient GIST.
← catalyst calendarNCT06640361 · readout in 224 d
Sponsored by Ascentage Pharma Group Inc. (industry) · AAPG — their whole pipeline →. With HealthQuest Pharma Inc..
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
40estimated
Sites
1
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-11 | actual | When the study began enrolling |
| Primary completion | 2027-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- GIST
Intervention
- Drug: Olverembatinib
Primary outcome
what the primary-completion date above is the date OFProgression-free survival(PFS) rate
measured 36 months
Permalink · AAPG's whole pipeline · Catalyst calendar · Every registered study · What changed